B-I gets (European) clearance for extended-release Parkinson’s drug formulation.
Avodart + Flomax – a good combo for your prostate? – The drug was shown, when given with tamsulosin, to have benefits for men with prostate enlargement. In the four-year CombAT study Avodart (dutasteride) and tamsulosin together showed a 66% reduction in the risk of acute urinary retention (AUR) or benign prostatic hyperplasia (BPH)-related surgery compared to tamsulosin alone. And the GSK-sponsored study, published online in European Urology, found a 20% risk reduction in these factors compared to Avodart on its own. Part of the results’ significance lies in the fact that tamsulosin is the active ingredient in Boehringer Ingelheim‘s Flomax, one of Avodart’s rivals in this therapy area…more
Glaxo starts getting hit with judgments over Paxil/birth defect link – A Pennsylvania state court jury deliberated seven hours before finding the drug maker failed to properly warn docs and pregnant women about the risks of the antidepressant. This was the first of 600 cases, by the way…more
From NPR – Selling Sickness: How drugs ads changed healthcare – It used to work like this: Doctors decided what to prescribe. Drug companies — through medical advertisers — tried to influence doctors. Patients did what they were told…more
Leadership and Management Development. Impactiviti’s partner network has a broad range of offerings, from assessments to customized workshops to simulations and much, much more. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for brainstorming and recommendations.
This is an imaginative and well-structured presentation on the U.S. healthcare system, in simple terms: Healthcare Napkins (named by BusinessWeek as one of the world’s best presentations of 2009)
JUST FOR FUN
Oct. 26-27 – Kru Research’s e-Patient Connections conference, Philadelphia, PA. I’ll be speaking and live-blogging. Here’s a discount code to save $500 off your registration: SW500
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff